Advertisement
UK markets closed

  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     

  • HANG SENG

    16,828.93
    +317.24 (+1.92%)
     

  • CRUDE OIL

    83.41
    +1.51 (+1.84%)
     

  • GOLD FUTURES

    2,341.10
    -5.30 (-0.23%)
     

  • DOW

    38,514.12
    +274.14 (+0.72%)
     

  • Bitcoin GBP

    53,573.56
    +148.65 (+0.28%)
     

  • CMC Crypto 200

    1,437.78
    +23.02 (+1.63%)
     

  • NASDAQ Composite

    15,724.87
    +273.56 (+1.77%)
     

  • UK FTSE All Share

    4,378.75
    +16.15 (+0.37%)
     
Money:

What is the true cost of the UK state pension?

To get a sense of the true value of the state pension, you can look at how much you would need to save to match it yourself

Synlogic (SYBX) Enters Cancer Collaboration with Roche

Zacks Equity Research

Synlogic, Inc. SYBX announced that it has entered a new collaboration with large pharma company, Roche RHHBY. Synlogic will develop its Synthetic Biotic medicine, SYNB1891, in combination with Roche’s PD-L1 inhibitor, Tecentriq (atezolizumab), as a treatment for advanced solid tumors.

SYNB1891 is a pre-clinical stage candidate. Synlogic is expected to file an investigational new drug (“IND”) application with the FDA in the second half of 2019to initiate a phase I study to evaluate SYNB1891 as monotherapy and in combination with Tecentriq.

The study will evaluate the maximum tolerated dose of SYNB1891 in patients as monotherapy and the recommended dose for the phase II study. Synlogic will bear the whole cost of the early-stage study and Roche will supply Tecentriq for clinical development.

Shares of Synlogic have increased 22.3% so far this year compared with the industry’s rise of 2.2%.

 

ADVERTISEMENT

SYNB1891 is a non-pathogenic strain of the bacteria, E.coli, which is designed to stimulate immune response in cancerous cells.

The checkpoint inhibitors like Merck’s MRK Keytruda and Bristol-Myers BMY and Roche’s Tecentriq have greatly improved the treatment outcomes in cancer patients. However, there are patients who are not responsive to these therapies. Synlogic expects the combination of natural therapies and adaptive therapies like the checkpoint inhibitors to generate better antitumor immune response.

Apart from SYNB1891, Synlogic has a few other candidates in its pipeline. The two lead candidates, SYNB1020 and SYNB1618, are being developed in phase I studies for hyperammonemia (a liver disease) and phenylketonuria, respectively. Synlogic also has a collaboration with AbbVie under which a candidate targeting inflammatory bowel disease is being developed.

Synlogic, Inc. Price

Synlogic, Inc. Price
Synlogic, Inc. Price

Synlogic, Inc. price | Synlogic, Inc. Quote

Zacks Rank

Synlogic currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Wall Street’s Next Amazon

Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.

Click for details >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Bristol-Myers Squibb Company (BMY) : Free Stock Analysis Report
 
Roche Holding AG (RHHBY) : Free Stock Analysis Report
 
Merck & Co., Inc. (MRK) : Free Stock Analysis Report
 
Synlogic, Inc. (SYBX) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research